Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (2018)	7/16/1998 10:09:00 PM
From: Linda Kaplan	Read Replies (1) \| Respond to of 2553

I settled for 5-5/8 today, too. My average price is still quite a bit higher. I haven't figured it out, lately, but it was 8 the last time I looked so maybe it's under 7 now. Thanks for all the good numbers and the humor. Only 10x, indeed. :-) Linda

To: Machaon who wrote (2018)	7/17/1998 5:49:00 AM
From: Skeeter Bug	Read Replies (1) \| Respond to of 2553

bob, i'm looking for genzl to aggressively grow applications. then, the market size could enlarge geometricly (sp?) ;-)

To: Machaon who wrote (2018)	7/18/1998 11:41:00 PM
From: Robert L. Ray	Read Replies (1) \| Respond to of 2553

Hi Bob, I see you invest in other bio's besides LGND. I have no GENZL position but FWIW I thought I'd mention that the latest Businessweek has a lengthy article on Bio-engineering tissue companies such as GENZL. It's the cover story. I'm not sure if it's available online. Here's the paragraph where they mention GENZL. Also included is the preceeding paragraph to give context. GENZL's skin product recieved no mention in the main text of the article although it was listed in one of the charts of various companies and their products. And to Linda K; Looks like I did OK on getting out of ASFT at 3 1/2. Now if only I hadn't used that money to buy Biti which has gone down from 1 1/2 to 27/32 :( OH well I do have a few winners though. I rode RPC from 9 7/8 before selling at 23 1/2 the other day, and bought yet more LGND with the proceeds. And CVD and GELX have been doing well. Now if only that darn LGND would perk up.... eh Bob:) Best of luck. From Businessweek magazine. Indeed, there are dozens of right ways in the works. Reprogenesis Inc. of Cambridge, Mass., for example, is in late-stage clinical trials with its method for using lab-grown cartilage to reinforce the urethra, a tube leading to the bladder. Weakened urethras can lead to incontinence, which afflicts an estimated 10 million people in the U.S., and reflux, a potentially fatal condition affecting about 1% of all infants in which urine backs up into the bladder. Reprogenesis removes a few cartilage cells from behind a patients ear, grows them in the lab, and then mixes them into a gel matrix. The cells are reinserted endoscopically where the urethra meets the bladder. There, they grow to bulk up the tubal walls. A knee-repair product called Carticel, approved by the FDA last August, uses somewhat the same principle. Made by Genzyme Tissue Repair, Carticel grows cartilage cells removed from the patient in the lab and then surgically reimplants them in the knee. No matrix is provided, however, so the cells can only be used to repair small rents. To replace the entire meniscus--that's th C-chaped pad in the knee betwen the thigh bone and shin bone--ReGen Biologics Inc. of Redwood City, Calif., is in clinical trials with a collagen scaffold in the shape of the meniscus. The pad is implanted in the knee to encourage regeneration of the patients's cartilage. Going a step further, Advanced Tissue Sciences is in preclinical trials with a meniscus-shaped cartilage grown in the lab that's meant to work in anyone. It hopes to start human tests by yearend.